DAVID FEIN: Open Payments
NPI 1225337124 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$343 in 14 payments from 7 companies in 2025. Trend: 2023 $48 · 2024 $172 · 2025 $343
Food & beverage: $286Education: $57
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Janssen Pharmaceuticals, Inc | 2 | $58 |
| SANOFI-AVENTIS U.S. LLC | 1 | $57 |
| Neurocrine BioSciences, Inc. | 2 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
Products named: REXULTI, INVEGA, DUPIXENT, INGREZZA, ABILIFY ASIMTUFII, UZEDY, COBENFY.
Industry payments across LA — which companies pay providers there.
